Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study)

Liu, YQ; Li, DD; Chai, M; Cong, HL; Cong, XQ; Dai, J; Du, RP; Gao, M; Guo, JC; Guo, YQ; Hong, XJ; Huang, RC; Jia, FS; Li, JY; Li, Q; Liu, JM; Liu, XP; Liu, YG; Nie, HG; Shao, B; Shen, XY; Song, HQ; Song, YJ; Wang, LJ; Wang, S; Wu, DM; Xia, J; Yang, ZY; Yu, HY; Zhang, H; Zhang, TM; Zhao, JY; Zhao, LC; Zheng, MQ; Chen, YD

Chen, YD (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Cardiol, Beijing, Peoples R China.

JOURNAL OF GERIATRIC CARDIOLOGY, 2021; 18 (4): 261

Abstract

BACKGROUND The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors were confirmed by several clinical trials, but......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索